Inbox Robot - Choose newsletter content

Choose content

Enter keywords to create a newsletter

Create account

Enter your registration information

Set preferences

Set up your newsletter name, delivery and time zone preferences

Hint: Enter different keywords to generate new results.

Now you can:

Search the news index.
Browse more than 1 million newsletters by category.
Use preset newsletters:

Bristol-Myers Squibb Newsletter

Bristol Myers Squibb, SystImmune report data from lung cancer trial 17 Oct 2025 15:35 GMT
Bristol Myers Squibb (NYSE:BMY) and SystImmune reported … developed collaboratively by SystImmune and Bristol Myers
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025 17 Oct 2025 14:49 GMT
… -stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today … biologics development. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical … ;systimmune.com/. Bristol Myers Squibb Cautionary Statement Regarding Forward- …
Bristol Myers Squibb describes new FAK degradation inducers 15 Oct 2025 19:06 GMT
Bristol Myers Squibb launches heart med Mavacamten in India 13 Oct 2025 15:09 GMT
… a blockbuster brand, US pharma Bristol Myers Squibb (BMS) has announced the … unmet need in treatment. Bristol Myers Squibb is committed to advancing cardiovascular …
Bristol Myers Squibb acquires Orbital Therapeutics for $1.5 billion 13 Oct 2025 16:49 GMT
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration 13 Oct 2025 13:40 GMT
… agreement between SystImmune and Bristol Myers Squibb. SystImmune is further eligible … vision with Bristol Myers Squibb." "Together with Bristol Myers Squibb, we have … -receive-milestone-payment-from-bristol-myers-squibb-under-iza-bren-collaboration …
<![CDATA[Gemcitabine intravesical system plus cetrelimab shows strong efficacy in MIBC]]> 18 Oct 2025 19:49 GMT
… /institutional funding from AstraZeneca, Bristol Myers Squibb, Gilead, Ipsen, and Merck … ;advisory fees from Astellas, AstraZeneca, Bristol Myers Squibb, Catalym, Gilead, Johnson …
<![CDATA[Adjuvant Nivolumab Displays Long-Term Activity in Resected Melanoma]]> 18 Oct 2025 18:59 GMT
… -Al Health, BioNTech, Boehringer-Ingelheim, Bristol Myers Squibb, Erasca, Genmab, ImCheck Therapeutics … ValoTx; receiving research funding from Bristol Myers Squibb, Medicenna, Pfizer, Regeneron, and …
<![CDATA[Dato-DXd Plus Rilvegostomig Elicits Activity in Cisplatin-Ineligible or Platinum-Pretreated Urothelial Cancer ]]> 18 Oct 2025 18:59 GMT
… Biosciences, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb/Ono, Daiichi Sankyo, Eisai … Pharma, AstraZeneca, Bayer, BeOne, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Indivumed, Eli …
<![CDATA[From Mutation to Medicine: Targeted Therapies in Lung Cancer]]> 18 Oct 2025 21:25 GMT
… ), crizotinib, and epotrectinib (Augtyro; Bristol Myers Squibb)—entering for resistant fusions,” said …

Satisfied with the content?

Continue to create your account.

Choose content

Create account

Set preferences

EIN MARKETING SOLUTIONS

EIN NEWS SERVICES

ALL NEWS PUBLICATIONS